Featured Research

from universities, journals, and other organizations

Insulin-sensitizing Drug Cut Diabetes Risk

Date:
April 12, 2005
Source:
NIH/ National Institute Of Diabetes And Digestive And Kidney Diseases
Summary:
Researchers report that troglitazone lowered diabetes onset by 75 percent compared to placebo during the time participants were taking the drug, an average period of nearly 11 months.

The Diabetes Prevention Program (DPP), a large clinical trial in people at high risk for developing type 2 diabetes, set out to compare four approaches to preventing diabetes. One of the study's initial goals was to test the insulin-sensitizing drug troglitazone, which was used in the DPP from 1996 until 1998, when researchers halted that part of the study due to the drug's toxicity in some participants. In a new analysis of DPP data published in the April 2005 issue of Diabetes, researchers report that troglitazone lowered diabetes onset by 75 percent compared to placebo during the time participants were taking the drug, an average period of nearly 11 months.

When the DPP was launched in 1995, researchers sought to compare four approaches to preventing type 2 diabetes in 3,819 overweight people with higher-than-normal blood glucose levels: dietary changes and increased physical activity aimed at a 7-percent weight loss; treatment with the oral diabetes drug metformin; treatment with troglitazone; or placebo. The last three groups were also given standard medical advice about diet and weight loss.

In June 1998 the investigators halted DPP's troglitazone arm because the drug caused liver toxicity in some volunteers and was linked to one participant's death. In 2000, the Food and Drug Administration withdrew the drug from the U.S. market after receiving additional reports suggesting liver toxicity was more serious and widespread than initially appreciated. DPP researchers continued monitoring all 585 participants who had taken the drug.

The study's main results were announced in 2001 and reported in the New England Journal of Medicine in 2002: losing 5 to 7 percent of body weight through diet and a modest, consistent increase in physical activity (e.g., walking 5 days a week 30 minutes a day) lowered the incidence of type 2 diabetes by 58 percent. Treatment with metformin lowered the chances of developing diabetes by 31 percent. For more information, see the NIH announcement of the DPP results.

"The analysis of DPP participants who received troglitazone shows the value of treating insulin resistance as a way to prevent type 2 diabetes," said Dr. William Knowler of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a study author and a DPP investigator. In insulin resistance, a condition that usually precedes type 2 diabetes, the cells in the body cannot use insulin effectively to convert glucose to energy and control blood glucose levels. "However, participants' exposure to troglitazone in the DPP was too short to draw firm conclusions about its long-term benefit in preventing or delaying type 2 diabetes," Knowler added. Analyzing the effects of the other treatment approaches for the same 11-month period, the researchers found that lifestyle changes reduced diabetes incidence by 58 percent, and treatment with metformin lowered it by 44 percent.

Troglitazone belongs to a class of drugs called the thiazolidinediones (TZDs), which make fat, muscle, and liver cells more sensitive to insulin. The TZDs currently approved by the FDA for the treatment of type 2 diabetes are Avandia (rosiglitazone) and Actos (pioglitazone), which have not been associated with the liver damage seen with troglitazone.

Industry-sponsored studies are currently looking at whether TZDs can prevent or delay type 2 diabetes in high-risk people. The NIH-funded TODAY study is comparing the combination of a TZD and metformin to other treatments in teens and children with type 2 diabetes.

"The good news from the DPP continues to be this: you can greatly lower the chances of getting type 2 diabetes by losing a modest amount of weight. Eating fewer calories and making physical activity a habit will help so many people stop or delay the disease before it becomes irreversible," said DPP study chair Dr. David Nathan of Massachusetts General Hospital, Boston.

About 40 percent of U.S. adults ages 40 to 74--41 million people--have abnormal blood glucose levels without having diabetes, which raises the risk of developing type 2 diabetes and cardiovascular disease. Many will develop type 2 diabetes in the next 10 years. (In the DPP, about 10 percent of participants in the placebo group developed diabetes each year.) Once a person has type 2 diabetes, the risk of heart and blood vessel disease is 2 to 4 times that of people without diabetes. (See tips on preventing type 2 diabetes developed by the National Diabetes Education Program, jointly sponsored by the National Institutes of Health and the Centers for Disease Control and Prevention.) About 18.2 million people-6.3 percent of the U.S. population-have diabetes. It is the main cause of kidney failure, limb amputations, and new onset blindness in adults and is a major cause of heart disease and stroke. Type 2 diabetes, the most common type of diabetes in adults, accounts for up to 95 percent of all diabetes cases. The prevalence of type 2 diabetes has risen dramatically in the last 30 years. In the last 10 years alone, the prevalence of diagnosed diabetes cases increased 50 percent, due mostly to the upsurge in obesity.

The DPP was funded by the following agencies of the U.S. Department of Health and Human Services: the NIDDK, the National Institute of Child Health and Human Development, the National Institute on Aging, the National Center on Minority Health and Health Disparities, the National Center for Research Resources, the Office of Research on Women's Health, and the Office of Behavioral and Social Science Research within the NIH as well as the Centers for Disease Control and Prevention and the Indian Health Service. The American Diabetes Association provided additional funding. Sources of corporate support included Bristol-Myers Squibb, Parke-Davis, Merck and Company, Merck Medco, Hoechst Marion Roussel, Sankyo, Lifescan, Lipha Pharmaceuticals, Slimfast, Nike, and Health-O-Meter.


Story Source:

The above story is based on materials provided by NIH/ National Institute Of Diabetes And Digestive And Kidney Diseases. Note: Materials may be edited for content and length.


Cite This Page:

NIH/ National Institute Of Diabetes And Digestive And Kidney Diseases. "Insulin-sensitizing Drug Cut Diabetes Risk." ScienceDaily. ScienceDaily, 12 April 2005. <www.sciencedaily.com/releases/2005/04/050411093425.htm>.
NIH/ National Institute Of Diabetes And Digestive And Kidney Diseases. (2005, April 12). Insulin-sensitizing Drug Cut Diabetes Risk. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2005/04/050411093425.htm
NIH/ National Institute Of Diabetes And Digestive And Kidney Diseases. "Insulin-sensitizing Drug Cut Diabetes Risk." ScienceDaily. www.sciencedaily.com/releases/2005/04/050411093425.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins